Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for ...

Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score ...

Breast cancer is a pervasive health concern that affects women globally, but its impact varies significantly across different demographics. Among these, Black women face unique challenges that ...

In a recent study, obesity was linked to an increased risk of recurrence for patients with HR-positive, early-stage breast cancer. Obesity was associated with an increased recurrence risk for patients ...

Follow-up overall survival, months, median (range) 96 (15-120) Follow-up PSA to recurrence or death, months, median (range) 55 (11-111) Follow-up PSA patients alive and recurrence-free, months, median ...

The likelihood of EGFR-positive lung cancer returning is largely tied to how advanced it is when first diagnosed, with lower chances in early stages and higher odds in later stages. Newer targeted ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

BOSTON — The risk for local recurrence of breast cancer decreases as event-free survival lengthens, according to an analysis of a large database from the Netherlands. The study, which also ...

MUSC Hollings Cancer Center researchers have unlocked a discovery that could help to explain why cancer can recur in patients who have undergone chemotherapy or radiotherapy. Both types of therapy put ...

Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes This retrospective analysis included patients with ...